Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLS006
MIFTS: 55

Plasmodium Vivax Malaria

Categories: Infectious diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Plasmodium Vivax Malaria

About this section

MalaCards integrated aliases for Plasmodium Vivax Malaria:

Name: Plasmodium Vivax Malaria 12 15 17
Malaria, Vivax 45 74
Malaria by Plasmodium Vivax 12
Vivax Malaria 12
Malaria Vivax 56

Classifications:

MalaCards categories:
Global: Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:12978
ICD9CM 36 084.1
MeSH 45 D016780
NCIt 51 C34800
SNOMED-CT 69 27052006
UMLS 74 C0024537
Sources

Summaries for Plasmodium Vivax Malaria

About this section
Disease Ontology : 12 A malaria that is caused by the protozoan parasite Plasmodium vivax, which induces paroxysms at 48-hour intervals.

MalaCards based summary : Plasmodium Vivax Malaria, also known as malaria, vivax, is related to malaria and mycobacterium tuberculosis 1. An important gene associated with Plasmodium Vivax Malaria is ACKR1 (Atypical Chemokine Receptor 1 (Duffy Blood Group)), and among its related pathways/superpathways are TGF-Beta Pathway and Allograft rejection. The drugs Primaquine and Artesunate have been mentioned in the context of this disorder. Affiliated tissues include testes, kidney and b cells, and related phenotypes are cardiovascular system and cellular

Sources

Related Diseases for Plasmodium Vivax Malaria

About this section

Diseases related to Plasmodium Vivax Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 313)
# Related Disease Score Top Affiliating Genes
1 malaria 30.8 ACKR1 ANGPT2 G6PD ICAM1 IFNG IL10
2 mycobacterium tuberculosis 1 30.5 IFNG IL10 TNF
3 hemophagocytic lymphohistiocytosis 30.5 IFNG IL10 TNF
4 pneumonia 30.5 IL10 IL6 TNF
5 myocarditis 30.5 ICAM1 IL6 TNF
6 bronchiolitis 30.2 IFNG IL10 IL6 TNF
7 bronchiolitis obliterans 30.2 IFNG IL10 IL6 TNF
8 appendicitis 30.1 IL10 IL6 TNF
9 adult respiratory distress syndrome 30.0 ANGPT2 IL10 IL6 TNF
10 meningitis 29.9 IFNG IL10 IL6 TNF
11 pulmonary edema 29.9 ICAM1 IL10 TNF
12 plasmodium falciparum malaria 29.3 G6PD ICAM1 IFNG IL10 SELE TNF
13 thrombocytopenia 10.8
14 acute respiratory distress syndrome 10.7
15 glucosephosphate dehydrogenase deficiency 10.5
16 trichosporonosis 10.5 IFNG TNF
17 microscopic colitis 10.5 IFNG TNF
18 crohn's colitis 10.5 IFNG TNF
19 tuberculous peritonitis 10.5 IFNG TNF
20 miliary tuberculosis 10.5 IFNG TNF
21 soft tissue sarcoma 10.4 IFNG TNF
22 staphylococcal toxic shock syndrome 10.4 IFNG TNF
23 chronic beryllium disease 10.4 IFNG TNF
24 retinitis pigmentosa 55 10.4 IL6 TNF
25 juvenile ankylosing spondylitis 10.4 IL6 TNF
26 endometrial disease 10.4 IL6 TNF
27 louse-borne relapsing fever 10.4 IL6 TNF
28 poems syndrome 10.4 IL6 TNF
29 glossitis 10.4 IL6 TNF
30 laryngitis 10.4 IL6 TNF
31 burning mouth syndrome 10.4 IL6 TNF
32 periapical periodontitis 10.4 IL6 TNF
33 acute vascular insufficiency of intestine 10.4 IL6 TNF
34 osteosclerotic myeloma 10.4 IL6 TNF
35 null-cell leukemia 10.4 IL6 TNF
36 b-cell growth factor 10.4 IFNG IL6
37 posterior urethral valves 10.4 IL6 TNF
38 stachybotrys chartarum 10.4 IL6 TNF
39 hemolytic-uremic syndrome 10.4
40 acute disseminated encephalomyelitis 10.4
41 cardiogenic shock 10.4 IL6 TNF
42 streptococcal toxic-shock syndrome 10.4 IL6 TNF
43 relapsing polychondritis 10.4 IFNG IL6
44 tungiasis 10.4 IL10 TNF
45 toxic oil syndrome 10.4 CYP2D6 IFNG
46 cow milk allergy 10.4 IL10 TNF
47 trachoma 10.4 IL10 TNF
48 choroiditis 10.4 IL10 TNF
49 trichuriasis 10.4 IL10 TNF
50 transient hypogammaglobulinemia 10.4 IL10 TNF

Graphical network of the top 20 diseases related to Plasmodium Vivax Malaria:



Diseases related to Plasmodium Vivax Malaria
Sources

Symptoms & Phenotypes for Plasmodium Vivax Malaria

About this section

MGI Mouse Phenotypes related to Plasmodium Vivax Malaria:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.06 ANGPT2 G6PD ICAM1 IFNG IL10 IL6
2 cellular MP:0005384 10.03 ANGPT2 G6PD ICAM1 IFNG IL10 IL6
3 homeostasis/metabolism MP:0005376 10.02 ACKR1 ANGPT2 G6PD ICAM1 IFNG IL10
4 immune system MP:0005387 9.92 ACKR1 ANGPT2 ICAM1 IFNG IL10 IL6
5 digestive/alimentary MP:0005381 9.88 ANGPT2 ICAM1 IFNG IL10 IL6 TNF
6 integument MP:0010771 9.8 ANGPT2 ICAM1 IFNG IL10 IL6 SELE
7 neoplasm MP:0002006 9.55 ICAM1 IFNG IL10 IL6 TNF
8 respiratory system MP:0005388 9.43 ANGPT2 IFNG IL10 IL6 SELE TNF
9 vision/eye MP:0005391 9.17 ANGPT2 ICAM1 IFNG IL10 IL6 SELE
Sources

Drugs & Therapeutics for Plasmodium Vivax Malaria

About this section

Drugs for Plasmodium Vivax Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Primaquine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90-34-6 4908
2
Artesunate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 88495-63-0 5464098 6917864
3
chloroquine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-05-7 2719
4
Artemether Approved Phase 4,Phase 3,Phase 1,Not Applicable 71963-77-4 68911 119380
5
Lumefantrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82186-77-4 6437380
6
Sulfadoxine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2447-57-6 17134
7
leucovorin Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-05-9 143 6006
8
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 58-14-0 4993
9
Mefloquine Approved, Investigational Phase 4,Phase 3 53230-10-7 4046
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 59-30-3 6037
11
Dihydroartemisinin Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71939-50-9 6918483
12
Piperaquine Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4085-31-8 5079497
13
Lactitol Investigational Phase 4,Phase 3 585-88-6, 585-86-4 493591
14 Antimalarials Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Chloroquine diphosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-63-5
17 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Artemisinine Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Artemisinins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Artemether, Lumefantrine Drug Combination Phase 4,Phase 3,Phase 1,Not Applicable
30 Vitamin B9 Phase 4,Phase 3,Phase 2,Not Applicable
31 Anti-Infective Agents, Urinary Phase 4,Phase 3,Phase 2,Not Applicable
32 Vitamin B Complex Phase 4,Phase 3,Phase 2,Not Applicable
33 Renal Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
35 Folate Phase 4,Phase 3,Phase 2,Not Applicable
36
Amodiaquine Approved, Investigational Phase 3,Not Applicable 86-42-0 2165
37
Dapsone Approved, Investigational Phase 3 80-08-0 2955
38
Proguanil Approved Phase 3 500-92-5 4923
39
Tafenoquine Approved, Investigational Phase 3,Phase 2,Phase 1 106635-80-7
40 Orange Approved Phase 3
41
Pyronaridine Investigational Phase 3,Phase 1 74847-35-1 5485198
42
Chlorproguanil Investigational Phase 3 537-21-3 9571037 151170
43
Imidacloprid Vet_approved Phase 3 105827-78-9 86418
44 Fanasil, pyrimethamine drug combination Phase 3,Phase 2,Not Applicable
45 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
46 Antimetabolites Phase 3
47
Methylene blue Approved, Investigational Phase 2 61-73-4
48
Tinidazole Approved, Investigational Phase 2 19387-91-8 5479
49 Vaccines Phase 1, Phase 2,Not Applicable,Early Phase 1
50 Alkylating Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand Unknown status NCT01662700 Phase 4 Artesunate;Chloroquine
2 Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam Unknown status NCT02610686 Phase 4 Chloroquine
3 Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam Completed NCT01887821 Phase 4 Chloroquine;Dihydroartemisinin/Piperaquine
4 Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Completed NCT01178021 Phase 4 Chloroquine;Chloroquine/Primaquine
5 Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia: Completed NCT02118090 Phase 4 Chloroquine sulfate;DHA-PP
6 A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI) Completed NCT02787070 Phase 4 PQ supervised;PQ unsupervised
7 A Study to Assess Current Standard Malaria Treatment Guidelines in the Republic of the Sudan Completed NCT02592408 Phase 4 ASP;SDPQ;14DPQ;14DPQ on Day 42
8 Effectiveness of Malaria Treatment in Mexico Completed NCT02394197 Phase 4 Chloroquine phosphate;primaquine
9 A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh Completed NCT02389374 Phase 4 chloroquine;Artemether-lumefantrine combination;Primaquine;Primaquine
10 G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria Recruiting NCT02876549 Phase 4 Chloroquine;Primaquine 0.25 mg/kg/day;Primaquine 0.75 mg/kg weekly
11 Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas - a Randomized Controlled Trial Not yet recruiting NCT03916003 Phase 4 primaquine
12 Assessing a Risk Model for G6PD Deficiency Suspended NCT03337152 Phase 4 primaquine;chloroquine + primaquine
13 Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV) Terminated NCT01107145 Phase 4 Mefloquine- Artesunate;Artemether-Lumefantrine;Chloroquine
14 Prevention of P. Vivax Malaria During Pregnancy in Bolivia Withdrawn NCT00290420 Phase 4 Chloroquine profilaxis
15 A Trial on Supervised Primaquine Use in Ethiopia Withdrawn NCT02793388 Phase 4 Supervised primaquine treatment;Unsupervised primaquine treatment
16 Artemether-lumefantrine vs Chloroquine for Uncomplicated P. Vivax Malaria in Malaysia Unknown status NCT02348788 Phase 3 Artemether-lumefantrine + Primaquine;Chloroquine + Primaquine
17 Study on the Treatment of Vivax Malaria Completed NCT01074905 Phase 3 Artesunate;Chloroquine;Chloroquine/Primaquine
18 Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria Completed NCT01288820 Phase 3 Dihydroartemisinin/piperaquine + primaquine;Artesunate-amodiaquine + primaquine
19 Artemether/Lumefantrine and Vivax Malaria Completed NCT01625871 Phase 3 tablets artemether/lumefantrine
20 Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria Completed NCT00440999 Phase 3 Pyronaridine artesunate;Chloroquine
21 Chlorproguanil/Dapsone Compared With Chloroquine and SP for Vivax Malaria Completed NCT00158561 Phase 3 sulfadoxine-pyrimethamine and chlorproguanil-dapsone
22 Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria Completed NCT02216123 Phase 3 Tafenoquine;Tafenoquine Placebo;Chloroquine;Primaquine;Primaquine Placebo
23 Eight Week Primaquine Regimen for the Treatment of Vivax Malaria Completed NCT00158587 Phase 3 primaquine
24 Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD) Completed NCT01640574 Phase 3 Dihydroartemisinin-Piperaquine;Dihydroartemisinin-Piperaquine;Chloroquine;Chloroquine
25 A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan Completed NCT00682578 Phase 3 Dihydroartemisinin + Piperaquine (Artekin);artesunate-sulphadoxin/pyrimethamine, chloroquine
26 Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria Completed NCT01378286 Phase 3 ARTESUNATE + AMODIAQUINE;Chloroquine
27 P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine Completed NCT01708876 Phase 3 Artesunate-mefloquine;Chloroquine;Primaquine
28 ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan Completed NCT00158548 Phase 3 SP, chloroquine, amodiaquine, primaquine, artesunate
29 Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon Completed NCT01845701 Phase 3 Artesunate-Amodiaquine;Dihydroartemisinine-Piperaquine;Artemether-lumefantrine combination
30 Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day Completed NCT02020330 Phase 3 Artemether-lumefantrine 3 days;Artemether-lumefantrine 5 days
31 Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine for Plasmodium Vivax Infection Completed NCT02691910 Phase 2, Phase 3 Chloroquine;Primaquine
32 Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria Recruiting NCT02802501 Phase 3 Tafenoquine;Matched-Placebo for Tafenoquine;Primaquine;Matched-Placebo for Primaquine;Dihydroartemisinin-piperaquine (DHA-PQP);ACT plus PQ (Rescue medication);PQ (End of study treatment)
33 DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil Recruiting NCT03208907 Phase 3 CQ coadministered with PQ;DHA-PQP coadministered with PQ;CQ and PQ starting on Day 42;DHA-PQP and PQ starting on Day 42
34 Methylene Blue Against Vivax Malaria in Ethiopia Unknown status NCT02696928 Phase 2 Artemeter-Lumefantrine and MB (combination therapy);Artemeter-Lumefantrine (combination therapy);Artemeter-Lumefantrine and Primaquine (combination therapy)
35 Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection Completed NCT01213966 Phase 2 OZ439
36 DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax Completed NCT02123290 Phase 2 DSM265 400mg;DSM265 xmg;DSM265 ymg
37 Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria Completed NCT00486694 Phase 2 Sulfadoxine-pyrimethamine + artesunate;Chloroquine
38 Study of VMP001 and AS01B in Healthy Malaria-Naïve Adults Completed NCT01157897 Phase 1, Phase 2
39 Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection Completed NCT01524341 Phase 2 KAE609
40 Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse Completed NCT01376167 Phase 2 Chloroquine 600mg;Chloroquine 300mg;Tafenoquine 50mg;Tafenoquine 100mg;Tafenoquine 300mg;Tafenoquine 600mg;Primaquine 15mg;Chloroquine 600mg (Part 2 );Chloroquine 300mg (Part 2 );Tafenoquine 300mg (Part 2);Primaquine 15mg (Part2 )
41 Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection Completed NCT01753323 Phase 2 KAF156
42 Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax Completed NCT00811096 Phase 2 Tinidazole;chloroquine
43 Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients Recruiting NCT03529396 Phase 2 Chloroquine;Primaquine;Primaquine;Chloroquine;Primaquine
44 A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria Recruiting NCT02563496 Phase 2 Tafenoquine;Chloroquine
45 MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria Suspended NCT02880241 Phase 2 MMV390048
46 Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria Terminated NCT02110784 Phase 2 Eurartesim tablets
47 Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults Terminated NCT01290601 Phase 2 Tafenoquine;Chloroquine + Primaquine;tafenoquine;Chloroquine + Primaquine
48 A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection Terminated NCT02573857 Phase 1, Phase 2 DSM265;OZ439
49 PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria Completed NCT00295581 Phase 1 PpPfs25/ISA51 & ScPvs25/ISA51
50 G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine) Completed NCT01205178 Phase 1 Chloroquine;Primaquine;Tafenoquine

Search NIH Clinical Center for Plasmodium Vivax Malaria

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: malaria, vivax

Sources

Genetic Tests for Plasmodium Vivax Malaria

About this section
Sources

Anatomical Context for Plasmodium Vivax Malaria

About this section

MalaCards organs/tissues related to Plasmodium Vivax Malaria:

42
Testes, Kidney, B Cells, Eye, T Cells, Whole Blood, Skin
Sources

Publications for Plasmodium Vivax Malaria

About this section

Articles related to Plasmodium Vivax Malaria:

(show top 50) (show all 612)
# Title Authors Year
1
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. ( 31067383 )
2019
2
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. ( 31067384 )
2019
3
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. Reply. ( 31067385 )
2019
4
Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Guragae zone southern Central Ethiopia. ( 31088384 )
2019
5
Profiles of hematological parameters in Plasmodium falciparum and Plasmodium vivax malaria patients attending Tercha General Hospital, Dawuro Zone, South Ethiopia. ( 30881057 )
2019
6
Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data. ( 30881061 )
2019
7
Duffy antigen receptor for chemokines (DARC) and susceptibility to Plasmodium vivax malaria. ( 30928426 )
2019
8
Imported Plasmodium vivax Malaria in the Russian Federation from Western Sub-Saharan Africa. ( 30936925 )
2019
9
Safety of primaquine in infants with Plasmodium vivax malaria in Papua, Indonesia. ( 30940140 )
2019
10
Five cases of Plasmodium vivax malaria treated with artemisinin derivatives: the advantages of a unified approach to treatment. ( 30809760 )
2019
11
Monitoring the Efficacy of Chloroquine-Primaquine Therapy for Uncomplicated Plasmodium vivax Malaria in the Main Transmission Hotspot of Brazil. ( 30782991 )
2019
12
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. ( 30650322 )
2019
13
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. ( 30650326 )
2019
14
Evaluation of Plasmodium vivax malaria recurrence in Brazil. ( 30670020 )
2019
15
Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria. ( 30102351 )
2019
16
High Risk of Plasmodium vivax Malaria Following Splenectomy in Papua, Indonesia. ( 29771281 )
2019
17
Chloroquine-Primaquine Therapeutic Efficacy, Safety, and Plasma Levels in Patients with Uncomplicated Plasmodium vivax Malaria in a Colombian Pacific Region. ( 30457097 )
2019
18
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. ( 30952158 )
2018
19
Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria. ( 30646129 )
2018
20
Concomitant Plasmodium vivax malaria and murine typhus infection with pulmonary involvement. ( 30567216 )
2018
21
Use of anthropophilic culicid-based xenosurveillance as a proxy for Plasmodium vivax malaria burden and transmission hotspots identification. ( 30418971 )
2018
22
Severe Plasmodium vivax malaria, HIV, tuberculosis co-infection in a Sri Lankan traveller: case management and challenges during the prevention of malaria reintroduction phase. ( 30445967 )
2018
23
On the epidemiology of Plasmodium vivax malaria: past and present with special reference to the former USSR. ( 30286752 )
2018
24
Screening and identification of potential novel biomarker for diagnosis of complicated Plasmodium vivax malaria. ( 30286756 )
2018
25
Susceptibility to Plasmodium vivax malaria associated with DARC (Duffy antigen) polymorphisms is influenced by the time of exposure to malaria. ( 30218021 )
2018
26
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure. ( 30269312 )
2018
27
Improving Plasmodium vivax malaria treatment: a little more chloroquine. ( 30033232 )
2018
28
Epidemiology of Plasmodium vivax Malaria Infection in Nepal. ( 30014810 )
2018
29
No risk reduction for Plasmodium vivax malaria in sickle cell disease. ( 29881595 )
2018
30
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. ( 29889239 )
2018
31
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study. ( 29909069 )
2018
32
Epidemiology, drug resistance, and pathophysiology of Plasmodium vivax malaria. ( 29916441 )
2018
33
Therapeutic and Transmission-Blocking 
Efficacy of Dihydroartemisinin/Piperaquine and Chloroquine against Plasmodium vivax Malaria, Cambodia. ( 29798745 )
2018
34
Polymorphisms in TLRs influence circulating cytokines production in Plasmodium vivax malaria: TLR polymorphisms influence cytokine productions in malaria-vivax. ( 29656958 )
2018
35
The Hidden Burden of Plasmodium vivax Malaria in Pregnancy in the Amazon: An Observational Study in Northwestern Brazil. ( 29741155 )
2018
36
Chloroquine resistance is associated to multi-copy pvcrt-o gene in Plasmodium vivax malaria in the Brazilian Amazon. ( 30012145 )
2018
37
Neurological complications in patients with Plasmodium vivax malaria from Karachi, Pakistan. ( 30191906 )
2018
38
Neurological involvement associated with Plasmodium vivax malaria from Pakistan. ( 28792284 )
2018
39
Development of Visually Improved Loop Mediated Isothermal Amplification for the Diagnosis of Plasmodium vivax Malaria in a Tertiary Hospital in Chandigarh, North India. ( 29557335 )
2018
40
Biological concepts in recurrent Plasmodium vivax malaria. ( 29564998 )
2018
41
Distinct inflammatory profile underlies pathological increases in creatinine levels associated with Plasmodium vivax malaria clinical severity. ( 29596409 )
2018
42
Genetic Spatiotemporal Anatomy of Plasmodium vivax Malaria Episodes in Greece, 2009-2013. ( 29460743 )
2018
43
CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study. ( 29390987 )
2018
44
Clinical and immunological profiles of anaemia in children and adolescents with Plasmodium vivax malaria in the Pará state, Brazilian Amazon. ( 29408596 )
2018
45
Case Report: Severe Plasmodium vivax Malaria Mimicking Sepsis in a Neonate. ( 29313481 )
2018
46
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms. ( 29357870 )
2018
47
Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial. ( 29361939 )
2018
48
Autoimmune Hemolytic Anemia in Plasmodium vivax Malaria. ( 28290054 )
2017
49
Metabolome-wide association study of peripheral parasitemia in Plasmodium vivax malaria. ( 28927849 )
2017
50
Outbreak Investigation of Plasmodium vivax Malaria in a Region of Guatemala Targeted for Malaria Elimination. ( 28138056 )
2017
Sources

Variations for Plasmodium Vivax Malaria

About this section
Sources

Expression for Plasmodium Vivax Malaria

About this section
Search GEO for disease gene expression data for Plasmodium Vivax Malaria.
Sources

Pathways for Plasmodium Vivax Malaria

About this section

Pathways related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

(show all 47)
# Super pathways Score Top Affiliating Genes
1
TGF-Beta Pathway 65
Show member pathways
 13.42 ANGPT2 ICAM1 IFNG IL10 IL6 TNF
2
Allograft rejection 38 1
Show member pathways
 12.79 ICAM1 IFNG IL10 IL6 TNF
3
Th17 cell differentiation 38
Show member pathways
 12.5 IFNG IL10 IL6 TNF
4
Immune response IL-23 signaling pathway 23
Show member pathways
 12.49 ANGPT2 IFNG IL10 IL6 TNF
5
T cell receptor signaling pathway 38
Show member pathways
 12.48 IFNG IL10 IL6 TNF
6
Selenium Micronutrient Network 1
Show member pathways
 12.27 ICAM1 IFNG IL6 TNF
7
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.17 IFNG IL10 IL6 TNF
8
Tuberculosis 38
12.16 IFNG IL10 IL6 TNF
9
C-type lectin receptor signaling pathway 38
Show member pathways
 12.11 IL10 IL6 TNF
10
Bacterial infections in CF airways 23
Show member pathways
 12.08 IFNG IL6 TNF
11
Colorectal Cancer Metastasis 65
12.08 IFNG IL6 TNF
12
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.07 IL10 IL6 TNF
13
Fluid shear stress and atherosclerosis 38
12.02 ICAM1 IFNG SELE TNF
14
Immune response IFN gamma signaling pathway 23
Show member pathways
 12 ANGPT2 ICAM1 IFNG IL10 IL6
15
Th1 Differentiation Pathway 66
Show member pathways
 11.98 IFNG IL10 IL6 TNF
16
Microglia Activation During Neuroinflammation: Overview 66
Show member pathways
 11.95 IFNG IL6 TNF
17
Spinal Cord Injury 1
11.93 ICAM1 IFNG IL6 TNF
18
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.9 IFNG IL10 IL6 TNF
19
Interleukin-4 and 13 signaling 67
11.88 ICAM1 IL10 IL6 TNF
20
TNF signaling pathway 38
11.85 ICAM1 IL6 SELE TNF
21
HIF-1 signaling pathway 38
11.83 ANGPT2 IFNG IL6
22
AGE-RAGE signaling pathway in diabetic complications 38
11.8 ICAM1 IL6 SELE TNF
23
Jak-Stat Signaling Pathway (sino) 68
11.79 IFNG IL10 IL6
24
Amoebiasis 38
11.76 IFNG IL10 IL6 TNF
25
Innate Lymphoid Cell Differentiation Pathways 66
11.73 IFNG IL10 TNF
26
Rheumatoid arthritis 38
11.72 ICAM1 IFNG IL6 TNF
27
Pertussis 38
11.7 IL10 IL6 TNF
28
Glucocorticoid receptor regulatory network 1
11.65 ICAM1 IFNG IL6 SELE
29
Dendritic Cells Developmental Lineage Pathway 66
11.57 IFNG IL10 IL6 TNF
30
ATF-2 transcription factor network 1
11.55 IFNG IL6 SELE
31
Microglia Activation During Neuroinflammation: Microglia Polarization 66
11.52 IFNG IL10 IL6 TNF
32
Photodynamic therapy-induced AP-1 survival signaling. 1
11.51 IFNG IL6 TNF
33
amb2 Integrin signaling 1
11.48 ICAM1 IL6 TNF
34
Transcription_Role of VDR in regulation of genes involved in osteoporosis 23
11.44 IFNG IL6 TNF
35
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.35 ICAM1 IFNG IL6 SELE TNF
36
IL-10 Pathway 65
11.32 IL10 IL6 TNF
37
Interleukin-10 signaling 67
11.31 ICAM1 IL10 IL6 TNF
38
Development and heterogeneity of the ILC family 1
11.27 IFNG IL6 TNF
39
G-protein signaling_RhoB regulation pathway 23
11.15 ANGPT2 IL10 IL6 TNF
40
OX40 Pathway 65
11.11 IFNG IL10
41
IL1 and megakaryocytes in obesity 1
11.09 ICAM1 IFNG
42
Transcription factor regulation in adipogenesis 1
11.02 IL6 TNF
43
Cytokines and Inflammatory Response 1
11.02 IFNG IL10 IL6 TNF
44
African trypanosomiasis 38
11 ICAM1 IFNG IL10 IL6 SELE TNF
45
Overview of nanoparticle effects 1
10.96 IL6 TNF
46
LDL Oxidation in Atherogenesis 65
10.88 ICAM1 TNF
47
Malaria 38
10.86 ACKR1 ICAM1 IFNG IL10 IL6 SELE
Sources

GO Terms for Plasmodium Vivax Malaria

About this section

Cellular components related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.17 ANGPT2 ICAM1 IFNG IL10 IL6 SELE

Biological processes related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.95 IFNG IL10 IL6 TNF
2 regulation of signaling receptor activity GO:0010469 9.93 IFNG IL10 IL6 TNF
3 cytokine-mediated signaling pathway GO:0019221 9.85 ICAM1 IL10 IL6 TNF
4 response to lipopolysaccharide GO:0032496 9.81 ICAM1 IL10 SELE
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 ICAM1 IL6 TNF
6 response to organic cyclic compound GO:0014070 9.77 ANGPT2 G6PD ICAM1
7 positive regulation of DNA-binding transcription factor activity GO:0051091 9.74 IL10 IL6 TNF
8 leukocyte migration GO:0050900 9.73 ANGPT2 ICAM1 SELE TNF
9 response to glucocorticoid GO:0051384 9.7 IL10 IL6 TNF
10 negative regulation of neurogenesis GO:0050768 9.65 IL6 TNF
11 positive regulation of protein complex assembly GO:0031334 9.64 IFNG TNF
12 positive regulation of osteoclast differentiation GO:0045672 9.63 IFNG TNF
13 humoral immune response GO:0006959 9.63 IFNG IL6 TNF
14 positive regulation of chemokine production GO:0032722 9.62 IL6 TNF
15 leukocyte tethering or rolling GO:0050901 9.61 SELE TNF
16 positive regulation of glial cell proliferation GO:0060252 9.61 IL6 TNF
17 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.59 IFNG TNF
18 negative regulation of growth of symbiont in host GO:0044130 9.58 IL10 TNF
19 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.58 IL10 TNF
20 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.58 DDX39B IL10 TNF
21 negative regulation of lipid storage GO:0010888 9.56 IL6 TNF
22 endothelial cell apoptotic process GO:0072577 9.54 IL10 TNF
23 positive regulation of nitric oxide biosynthetic process GO:0045429 9.54 ICAM1 IFNG TNF
24 negative regulation of cytokine secretion involved in immune response GO:0002740 9.51 IL10 TNF
25 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.49 ICAM1 TNF
26 positive regulation of neuroinflammatory response GO:0150078 9.48 IL6 TNF
27 cellular response to lipopolysaccharide GO:0071222 9.46 ICAM1 IL10 IL6 TNF
28 inflammatory response GO:0006954 9.35 ACKR1 IL10 IL6 SELE TNF
29 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.32 IFNG TNF
30 receptor biosynthetic process GO:0032800 9.26 IL10 TNF
31 positive regulation of vitamin D biosynthetic process GO:0060557 8.62 IFNG TNF

Molecular functions related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 IFNG IL10 IL6 TNF
Sources

Sources for Plasmodium Vivax Malaria

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....